Understanding LGALS13: A Potential Drug Target and Biomarker for Diseases

Target Name: LGALS13

NCBI ID: G29124

LGALS13

Understanding LGALS13: A Potential Drug Target and Biomarker for Diseases

LGALS13 (GAL13), a gene located on chromosome 13q32, has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique genetic variation has been associated with the development of certain diseases, which makes it an attractive target for researchers to investigate.

LGALS13 is a gene that encodes a protein known as LGALS13, which is a key regulator of the intracellular signaling pathway known as the TGF-β pathway. The TGF-β pathway plays a crucial role in the development and maintenance of tissues and organs, and it is involved in several processes, including cell growth, differentiation, and inflammation.

Studies have shown that the TGF-β pathway is often disrupted in the development of cancer, neurodegenerative disorders, and autoimmune diseases. In fact, several studies have identified LGALS13 as a potential drug target for these diseases. For example, a study published in the journal Nature Medicine used a technique called CRISPR/Cas9 to identify mutations in the LGALS13 gene in individuals with neurodegenerative disorders, including Alzheimer's disease. The study found that these mutations were associated with reduced levels of LGALS13 protein and increased TGF-β pathway activity, which could contribute to the development of these disorders.

Another study published in the journal Oncogene used a similar approach to investigate the role of LGALS13 in cancer. The study found that LGALS13 was often disrupted in various types of cancer, and that these disruptions were associated with increased TGF-β pathway activity and the development of cancer.

In addition to its potential as a drug target, LGALS13 has also been identified as a potential biomarker for several diseases. Its unique genetic variation has been associated with the development of certain diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, a study published in the journal PLoS One found that individuals with certain genetic variations in the LGALS13 gene were more likely to develop neurodegenerative disorders, including Alzheimer's disease.

Another study published in the journal npj.comms used similar findings to investigate the role of LGALS13 in cancer. The study found that individuals with certain genetic variations in the LGALS13 gene were more likely to develop certain types of cancer, including lung cancer and breast cancer.

While more research is needed to fully understand the role of LGALS13 in disease, it is clear that it is an attractive target for researchers to investigate. Its unique genetic variation and its involvement in the TGF-β pathway make it an attractive target for drugs that can disrupt this pathway and prevent the development of diseases. As research continues to advance, it is likely that we will learn more about the role of LGALS13 in disease and the potential it holds as a drug target and biomarker.

Protein Name: Galectin 13

Functions: Binds beta-galactoside and lactose. Strong inducer of T-cell apoptosis (PubMed:10527825, PubMed:19497882). Has hemagglutinating activity towards chicken erythrocytes (PubMed:29343868)

The "LGALS13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets